A rebuttal letter to the letter ID number CLRH-D-21�00,836 entitled �On the efficacy and safety of rituximab therapy in patients with systemic sclerosis disease: missing points, bottlenecks, over-exaggeration and discrepancies�

Authors
Publication date
1 January 2021
Publisher
Springer Science and Business Media Deutschland GmbH

Abstract

Abstract is not available.

    Similar works

    Full text

    thumbnail-image

    Available Versions

    Golestan University of Medical Sciences Repository

    redirect
    oaioai:eprints.goums.ac.ir:11230
    Last time updated on 03/12/2021